GLP1R and metabolic dysfunction-associated steatohepatitis: Importantly, given that sex-related differences in the prevalence, risk factors and clinical outcomes of NAFLD are a distinctive and recently identified feature of NAFLD and NASH [59,60], future adequately powered RCTs should be specifically designed to explore sex differences in the response rate of NAFLD and NASH to treatment with GLP-1 RAs.